U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07385287) titled 'Phase 2 Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults' on Jan. 27.
Brief Summary: This is a Phase 2 clinical trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria(R) PfSPZ-LARC2 Vaccine). It represents the next step in the development of this vaccine toward licensure, following a successful Phase 1 program in which the vaccine was shown to be safe (fully attenuated), well tolerated and immunogenic in malaria-exposed 1- to 45-year-olds in Burkina Faso (BFSPZL1 trial) and in malaria-naive adults in the US (USSPZL1 trial). Protection data will be available ...